This event has passed.

Duke team co-authors state of the art review on ALS trials, clinical endpoints and biomarkers.

Name: Duke team co-authors state of the art review on ALS trials, clinical endpoints and biomarkers.
Start: 2022-10-17T00:00:00-04:00
End: 2022-10-17T23:59:59-04:00

October 17, 2022 All day

Duke team co-authors state of the art review on ALS trials, clinical endpoints and biomarkers.

You can read it here

Event Navigation

« Dr. Bedlack presented a short talk called “Untangling the ALS X-Files” at the Duke Forever Learning Institute’s “Fortifying the Brain” program.
Duke team presents results of Theracurmin trial at NEALS meeting. »